These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 20163193)
1. Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice. Kudo T; Toda T; Ushiki T; Ohi K; Ikarashi N; Ochiai W; Sugiyama K Xenobiotica; 2010 Apr; 40(4):282-90. PubMed ID: 20163193 [TBL] [Abstract][Full Text] [Related]
2. Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity. Kudo T; Shimada T; Toda T; Igeta S; Suzuki W; Ikarashi N; Ochiai W; Ito K; Aburada M; Sugiyama K Xenobiotica; 2009 Dec; 39(12):889-902. PubMed ID: 19925381 [TBL] [Abstract][Full Text] [Related]
3. Insulin in flavin-containing monooxygenase regulation. Flavin-containing monooxygenase and cytochrome P450 activities in experimental diabetes. Borbás T; Benko B; Dalmadi B; Szabó I; Tihanyi K Eur J Pharm Sci; 2006 May; 28(1-2):51-8. PubMed ID: 16488120 [TBL] [Abstract][Full Text] [Related]
4. Effects of enzyme induction therapy on glucose and drug metabolism in obese mice model of non-insulin dependent diabetes mellitus. Karvonen I; Stengård JH; Huupponen R; Stenbäck FG; Sotaniemi EA Diabetes Res; 1989 Feb; 10(2):85-92. PubMed ID: 2501061 [TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and low sympathetic nerve activity in the Tsumura Suzuki obese diabetic mouse: a new model of spontaneous type 2 diabetes mellitus and obesity. Takahashi A; Tabuchi M; Suzuki W; Iizuka S; Nagata M; Ikeya Y; Takeda S; Shimada T; Aburada M Metabolism; 2006 Dec; 55(12):1664-9. PubMed ID: 17142141 [TBL] [Abstract][Full Text] [Related]
6. Separate influences of insulin and hyperglycemia on hepatic drug metabolism in mice with genetic and chemically induced diabetes mellitus. Knodell RG; Handwerger BS; Morley JE; Levine AS; Brown DM J Pharmacol Exp Ther; 1984 Jul; 230(1):256-62. PubMed ID: 6379147 [TBL] [Abstract][Full Text] [Related]
7. Increased gene expression of antioxidant enzymes in KKAy diabetic mice but not in STZ diabetic mice. Fujita A; Sasaki H; Ogawa K; Okamoto K; Matsuno S; Matsumoto E; Furuta H; Nishi M; Nakao T; Tsuno T; Taniguchi H; Nanjo K Diabetes Res Clin Pract; 2005 Aug; 69(2):113-9. PubMed ID: 16005359 [TBL] [Abstract][Full Text] [Related]
8. Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression. Perloff MD; Von Moltke LL; Greenblatt DJ Xenobiotica; 2003 Apr; 33(4):365-77. PubMed ID: 12745872 [TBL] [Abstract][Full Text] [Related]
9. Characteristics of bone strength and metabolism in type 2 diabetic model Tsumura, Suzuki, Obese Diabetes mice. Tanaka H; Yamashita T; Yoneda M; Takagi S; Miura T Bone Rep; 2018 Dec; 9():74-83. PubMed ID: 30094297 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of the intestinal flora in type 2 diabetes and nondiabetic mice. Horie M; Miura T; Hirakata S; Hosoyama A; Sugino S; Umeno A; Murotomi K; Yoshida Y; Koike T Exp Anim; 2017 Oct; 66(4):405-416. PubMed ID: 28701620 [TBL] [Abstract][Full Text] [Related]
11. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Lampen A; Christians U; Guengerich FP; Watkins PB; Kolars JC; Bader A; Gonschior AK; Dralle H; Hackbarth I; Sewing KF Drug Metab Dispos; 1995 Dec; 23(12):1315-24. PubMed ID: 8689938 [TBL] [Abstract][Full Text] [Related]
12. Beta-cell function and mass in type 2 diabetes. Larsen MO Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971 [TBL] [Abstract][Full Text] [Related]
13. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine. Zhang QY; Kaminsky LS; Dunbar D; Zhang J; Ding X Drug Metab Dispos; 2007 Sep; 35(9):1617-23. PubMed ID: 17567730 [TBL] [Abstract][Full Text] [Related]
14. Characterization of mouse small intestinal cytochrome P450 expression. Zhang QY; Dunbar D; Kaminsky LS Drug Metab Dispos; 2003 Nov; 31(11):1346-51. PubMed ID: 14570766 [TBL] [Abstract][Full Text] [Related]
15. Effect of age on in vitro triazolam biotransformation in male human liver microsomes. Patki KC; von Moltke LL; Harmatz JS; Hesse LM; Court MH; Greenblatt DJ J Pharmacol Exp Ther; 2004 Mar; 308(3):874-9. PubMed ID: 14634046 [TBL] [Abstract][Full Text] [Related]
16. Experimental type 2 diabetes induces enzymatic changes in isolated rat enterocytes. Martínez IM; Morales I; García-Pino G; Campillo JE; Tormo MA Exp Diabesity Res; 2003; 4(2):119-23. PubMed ID: 14630573 [TBL] [Abstract][Full Text] [Related]
17. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Thummel KE; Schenkman JB Mol Pharmacol; 1990 Jan; 37(1):119-29. PubMed ID: 2105452 [TBL] [Abstract][Full Text] [Related]
18. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model. Nawa A; Fujita-Hamabe W; Tokuyama S Life Sci; 2011 Dec; 89(23-24):834-8. PubMed ID: 21983297 [TBL] [Abstract][Full Text] [Related]
19. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme activity in retinas of streptozotocin-induced and Zucker diabetic rats. The effect of angiotensin II on Na+,K(+)-ATPase activity. Ottlecz A; Bensaoula T; Eichberg J; Peterson RG Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2157-64. PubMed ID: 8843902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]